Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Pediatric heart transplantation: how to manage problems affecting long-term outcomes?

  • Kim, Young Hwue (Department of Pediatric Cardiology, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
  • Received : 2019.11.13
  • Accepted : 2020.04.08
  • Published : 2021.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Since the initial International Society of Heart Lung Transplantation registry was published in 1982, the number of pediatric heart transplantations has increased markedly, reaching a steady state of 500-550 transplantation annually and occupying up to 10% of total heart transplantations. Heart transplantation is considered an established therapeutic option for patients with end-stage heart disease. The long-term outcomes of pediatric heart transplantations were comparable to those of adults. Issues affecting long-term outcomes include acute cellular rejection, antibody-mediated rejection, cardiac allograft vasculopathy, infection, prolonged renal dysfunction, and malignancies such as posttransplant lymphoproliferative disorder. This article focuses on medical issues before pediatric heart transplantation, according to the Korean Network of Organ Sharing registry and as well as major problems such as graft rejection and cardiac allograft vasculopathy. To reduce graft failure rate and improve long-term outcomes, meticulous monitoring for rejection and medication compliance are also important, especially in adolescents.

Keywords

References

  1. Kantrowitz A, Haller JD, Joos H, Cerruti MM, Carstensen HE. Transplantation of the heart an infant and an adult. Am J Cardiol 1968;22:782-90. https://doi.org/10.1016/0002-9149(68)90173-2
  2. Hertz MI. The registry of the international society for heart and lung transplantation- Introduction to the 2012 annual reports; New leadership, same version. J Heart and lung Transplant 2012;31;1045-95. https://doi.org/10.1016/j.healun.2012.08.003
  3. Rossano JW, Dipchand AI, Edward LB, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the international society for heart and lung transplantation: Nineteenth pediatric heart transplantation report-2016: Focus theme: Primary diagnostic indications for transplantation. J Heart Lung Transplant 2016;35;1185-95. https://doi.org/10.1016/j.healun.2016.08.018
  4. Hayes D Jr, Cherikh WS, Chambers DC, Harhay MO, Khush KK, Lehman RR, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric lung and heart-lung transplantation report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant 2019;38:1015-27. https://doi.org/10.1016/j.healun.2019.08.003
  5. Boyle GJ, Michaels MG. Evaluation of the candidate for heart transplantation. In: Tejani AH, Harmon WE, Fine RN, editors. Pediatric solid organ transplantation. Copenhagen (Denmark): Munksgaard, 2000:328-33.
  6. Webber SA. Evaluaton and management of the cardiac donor. In: Tejani AH, Harmon WE, Fine RN, editors. Pediatric solid organ transplantation. Copenhagen (Denmark): Munksgaard, 2000:342-7.
  7. Kanani M, Hoskote A, Carter C, Burch M, Tsang V, Kostolny M. Increasing donor-recipient weight mismatch in pediatric orthotopic heart transplantation does not adversely affect outcome. Eur J Cardiothorac Surg 2012;41:427-34. https://doi.org/10.1016/j.ejcts.2011.04.042
  8. Mahle WT, Tresler MA, Edens RE, Rusconi P, George JF, Naftel DC, et al. Allosensitization and outcomes in pediatric heart transplantation. J Heart Lung Transplant 2011;30:1221-7. https://doi.org/10.1016/j.healun.2011.06.005
  9. Asante-Korang A, Amankwah EK. Lopez-Cepero M, Ringewald J, Carapellucci J, Krasnopero D, et al. Outcomes in highly sensitized pediatric heart transplant patients using current management strategies. J Heart Lung Transplant 2015;34:175-81. https://doi.org/10.1016/j.healun.2014.09.027
  10. Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston CB, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing perioperative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007;26:876-82. https://doi.org/10.1016/j.healun.2007.07.011
  11. Kirk R, Edward LB, Aurora P, Taylor DO, Christie JD, Dobbels F, et al. Registry of the international society heart and lung transplantation: Twelfth official pediatric heart transplantation report-2009. J Heart Lung Transplant 2009;28:993-1006. https://doi.org/10.1016/j.healun.2009.08.008
  12. Gazit AZ, Fehr J. Perioperative management of the pediatric cardiac transplantation patient. Curr Treat Option in Cardiovasc Med 2011;13:425-43. https://doi.org/10.1007/s11936-011-0143-8
  13. Costanza MR. Special feature: The international society of heart and lung transplantation: guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29:914-56. https://doi.org/10.1016/j.healun.2010.05.034
  14. Baraldo M, Gregoraci G, Livi U. Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature. Transpl Int 2014;27:515-29. https://doi.org/10.1111/tri.12309
  15. Zuppan CW, Wells LM, Kerstetter JC, Johnston JK, Baily LL, Chinnock RE. Cause of death in pediatric and infant heart transplant recipients: review of a 20-year, single institution cohort. J Heart Lung Transplant 2009;28:579-84. https://doi.org/10.1016/j.healun.2009.02.012
  16. Profita EL, Gauvreau K, Rycus P, Thiagarajan R, Singh TP. Incidence, predictors, and outcomes after severe primary graft dysfunction in pediatric heart transplant recipients. J Heart Lung Transplant 2019;38:601-8. https://doi.org/10.1016/j.healun.2019.01.1310
  17. Patel JK, Kobashigawa JA. Should we be doing routine biopsy after heart transplantation in a new era of anti-rejection? Curr Opin Cardiol 2006;21:127-31. https://doi.org/10.1097/01.hco.0000210309.71984.30
  18. Bhat G, Burwig S, Walsh R. Morbidity of endomayocardial biopsy in cardiac transplant recipients. Am Heart J 1993;125:1180-1. https://doi.org/10.1016/0002-8703(93)90138-Y
  19. From AM, Maleszewski JJ, Rihal CS. Current status of endomyocardial biopsy. Mayo Clin Proc 2011;86:1095-102. https://doi.org/10.4065/mcp.2011.0296
  20. Flanagan R, Cain N, Tatum GH, DeBrunner MG, Drant S, Feingold B. Left ventricular myocardial performance index change for the detection of acute cellular rejection in pediatric heart transplantation. Pediatr Transplant 2013;17:782-6. https://doi.org/10.1111/petr.12153
  21. Aggarwal S, Blake J, Sehgal S. Right ventricular dysfunction as an echocardiographic measure of acute rejection following heart transplantation in children. Pediatr Cardiol 2017;38:442-7. https://doi.org/10.1007/s00246-016-1533-1
  22. Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valentine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the invasive monitoring attenuation through gene expression (IMAGE) trial. J Heart Lung Transplant 2007;26:808-14. https://doi.org/10.1016/j.healun.2007.05.017
  23. Pascual-Figal DA, Garrido IP, Blanco R, Minguela A, Lax A, Ordonez-Llanos J, et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg 2011;92:2118-24. https://doi.org/10.1016/j.athoracsur.2011.07.048
  24. Dyer AK, Barnes AP, Fixler DE, Shah TK, Sutcliffe DL, Hashim I, et al. Use of a highly sensitive assay for cardiac troponin T and N-terminal pro-brain natriuretic peptide to diagnose acute rejection in pediatric cardiac transplant recipients. Am Heart J 2012;163:595-600. https://doi.org/10.1016/j.ahj.2012.02.003
  25. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, et al. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant 2013;32:120-8. https://doi.org/10.1016/j.healun.2012.09.030
  26. Daly KP. Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine. Cardiol Young 2015;25 Suppl 2(Suppl 2):117-23. https://doi.org/10.1017/S1047951115000918
  27. Martinez-Dolz L, Almenar L, Reganon E, Vila V, Sanchez-Soriano R, Martinez-Sales V, et al. What is the best biomarker for diagnosis of rejection in the heart transplantation? Clin Tranplant 2009;23:672-80. https://doi.org/10.1111/j.1399-0012.2009.01074.x
  28. Mathews LR, Lott JM, Isse K, Lesniak A, Landsittel D, Demetris AJ, et al. Elevated ST2 distinguishes incidences of pediatric heart and small bowel transplant rejection. Am J Transplant 2016;16:938-50. https://doi.org/10.1111/ajt.13542
  29. Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006;6:150-60. https://doi.org/10.1111/j.1600-6143.2005.01175.x
  30. VanBuskirk AM, Pidwell DJ, Adams PW, Orosz CG. Transplantation immunology. JAMA 1997;278:1993-9. https://doi.org/10.1001/jama.1997.03550220199025
  31. Agbor-Enoh S, Tunc I, Vlaminck ID, Fideli U, Davis A, Cuttin K, et al. Applying rigor and reproducibility standards to assay donor-drived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation. J Heart Lung Transplant 2017;36:1004-12. https://doi.org/10.1016/j.healun.2017.05.026
  32. Khush KK, Patel J, Pinney S, Kao A, Alharethi R, DePasquale E, et al. Noninvasive detection of graft injury after heart transplant using donor-drived cell-free DNA: a prospective multicenter study. Am J Transplant 2019;19:2889-99. https://doi.org/10.1111/ajt.15339
  33. Mills RM, Naftel DC. Heart transplant rejection with hemodynamic compromise: a multiintstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant 1997;16:813-21.
  34. Pahl E, Naftel DC, Canter CE, Fraiser EA, Kirklin JK, Morrow WR, et al. Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients: a multi-institutional study. J Heart Lung Transplant 2001;20:279-87. https://doi.org/10.1016/s1053-2498(00)00228-x
  35. Phelps CM, Tissort C, Buckvold S, Gralla J, Ivy DD, Pietra BA, et al. Outcome of acute graft rejection associated with hemodynamic compromise in pediatric heart transplant recipients. Pediatr Cardiol 2011;32:1-7. https://doi.org/10.1007/s00246-010-9795-5
  36. Stoica S, MMath FC, Pauriah M, Taylor CJ, Sharples LD, Wallwork J, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006;25:420-5. https://doi.org/10.1016/j.healun.2005.11.449
  37. Herskowitz A, Soule LM, Ueda K, Tamura F, Baumgartner WA, Borkon AM, et al. Arteriolar vasculitis on endomyocardial biopsy: a histologic predictor of poor outcome in cyclosporine treated heart transplant recipients. J Heart Transplant 1987;6:127-36.
  38. Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Rainsmoen NL, et al. Acute antibody mediated rejection of cardiac transplants. J Heart Lung Transplant 2006;25:153-9. https://doi.org/10.1016/j.healun.2005.09.003
  39. Zakliczynski M, Nozynski J, Konecka-Mrowka D, Babinska A, Flak B, Hrakowitcz T, et al. Coincidence of cellular and antibody mediated rejection in heart transplant recipients-preliminary report. Kardiochir Torakochirurgia Pol 2014;11:52-5.
  40. Thrush PT, Pahl E, Naftel DC, Rruitt E, Everitt MD, Missler H, et al. A multi-institutional evaluation of antibody-mediated rejection utilizing the Pediatric Heart Transplant Study database: incidence, therapies and outcomes. J Heart Lung Transplant 2016;35:1497-504. https://doi.org/10.1016/j.healun.2016.06.014
  41. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, et al. Report from a concensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011;30:252-69. https://doi.org/10.1016/j.healun.2010.11.003
  42. Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2012;31:46-51. https://doi.org/10.1016/j.healun.2011.10.009
  43. Everitt MD, Hammon MEH, Snow GL, Stehlik J, Revelo MP, Miller DV, et al. Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant. J Heart Lung Transplant 2012;31:686-93. https://doi.org/10.1016/j.healun.2012.03.009
  44. Wu GW, Kowashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, et al. Asymptomatic antibody-mediated rejection after heart transplantation predict poor outcomes. J Heart Lung Transplant 2009;28:417-22. https://doi.org/10.1016/j.healun.2009.01.015
  45. Chin C. Cardiac antibody-mediated rejection. Pediatr Transplant 2012;16:404-12. https://doi.org/10.1111/j.1399-3046.2012.01690.x
  46. Roman-Oritz E, Oteiza SM, Pinto S, Lopez-Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol 2014;29:149-53. https://doi.org/10.1007/s00467-013-2591-8
  47. Castleberry C, Ryan TD, Chin C. Transplantation in the highly sensitized pediatric patient. Circulation 2014;129:2313-9. https://doi.org/10.1161/CIRCULATIONAHA.113.001378
  48. Kittleson MM. Changing role of heart transplantation. Heart Failure Clin 2016;12:411-21. https://doi.org/10.1016/j.hfc.2016.03.004
  49. Kowashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transplant 2011;25:E61-67. https://doi.org/10.1111/j.1399-0012.2010.01334.x
  50. Ware AL, Malmberg E, Delgado JC, Hammond ME, Miller DV, Stehlik J, et al. The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children. J Heart Lung Transplant 2016;35:179-85. https://doi.org/10.1016/j.healun.2015.10.006
  51. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemanm NE, Kobashigawa JA, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomencleature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010;29:717-27. https://doi.org/10.1016/j.healun.2010.05.017
  52. Kindel SJ, Law YM, Chin C, Burch M, Kirklin JK, Naftel DC, et al. Improved detection of cardiac allograft vasculopathy. A multi-institutional anaylsis of functional parmeters in pediatric heart transplant recipients. J Am Coll Cardiol 2015;66:547-57. https://doi.org/10.1016/j.jacc.2015.05.063
  53. Price JF, Towbin JA, Dreyer WJ, Radovancevic B, Rosenblatt HM, Clunie SK, et al. Symptom complex is associated with transplant coronary artery disease and sudden death/resuscitated sudden death in pediatric heart transplant recipients. J Heart Lung Transplant 2005;24:1798-803. https://doi.org/10.1016/j.healun.2005.03.013
  54. Jeewa A, Dreyer WJ, Kearney DL, Denfield SW. The presentation and diagnosis of coronary allograft vasculopathy in pediatric heart transplant recipients. Congenit Heart Dis 2012;7:302-11. https://doi.org/10.1111/j.1747-0803.2012.00656.x
  55. Pahl E, Naftel DC, Kuhn MA, Shaddy RE, Morrow WR, Canter CE, et al. The impact and outcome of transplant coronary artery disease in a pediatric population: 9-year multi-institutional study. J Heart Lung Transplant 2005;24:645-51. https://doi.org/10.1016/j.healun.2004.03.021
  56. Kirk R, Edward LB, Kucheryavaya AY, Aurora P, Christie JD, Dobbels F, et al. The registry of the International Society for Heart and Lung Transplantation: Thirteenth official pediatric heart transplantation report-2010. J Heart Lung Transplant 2010;29:1119-28. https://doi.org/10.1016/j.healun.2010.08.009
  57. Kobayashi D, Du W, L'Ecuyer TJ. Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients. Pediatr Transplant 2013;17:436-440. https://doi.org/10.1111/petr.12095
  58. Schumacher KR, Gajarski R, Urschel S. Pediatric coronary allograft vasculopathy - a review of pathogenesis and risk factors. Congenit Heart Dis 2012;7:312-23. https://doi.org/10.1111/j.1747-0803.2011.00601.x
  59. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantinevon Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003;349:847-58. https://doi.org/10.1056/NEJMoa022171
  60. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 2005;24:63-6. https://doi.org/10.1016/j.healun.2003.10.013
  61. Bae JH. Rihal CS, Edwards BS, Kuchwaha SS, Mathew V, Prasad A, et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plague regression in cardiac allograft vasculopathy. Transplantation 2006;82:1108-11. https://doi.org/10.1097/01.tp.0000230378.61437.a5
  62. Mehra MR, Uber PA, Potluri S, Ventura HO, Scott RL, Park MH. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J cardiol 2004;94:454-8. https://doi.org/10.1016/j.amjcard.2004.04.060
  63. Claudius I, Lan YT, Chang RK, Wetzel GT, Alejos J. Usefulness of B-type natriuretic peptide as a non-invasive screening tools for cardiac allograft pathology in pediatric heart transplant recipeints. Am J Cardiol 2003;92:1368-70. https://doi.org/10.1016/j.amjcard.2003.08.035
  64. Rossano JW, Denfield SW, Kim JJ, Price JF, Jefferies JL, Decker JA, et al. B-type natriuretic peptide level late after transplant predict graft survival in pediatric heart transplant patients. J Heart Lung Transplant 2010;29:385-6. https://doi.org/10.1016/j.healun.2009.06.002
  65. Asante-Korang A, Fickey M, Boucek MM, Boucek RJ Jr. Diastolic performance assessed by tissue doppler after pediatric heart transplantation. J Heart Lung Transplant 2004;23:865-72. https://doi.org/10.1016/j.healun.2003.08.004
  66. Sarvari SI, Gjesdal O, Gude E, Arora S, Andereassen AK, Gullestad L, et al. Early postoperative left ventricular function by echocardiographic strain is a predict of 1 year mortality in heart transplant reipients. J Am Soc Echocardiogr 2012;25:1007-14. https://doi.org/10.1016/j.echo.2012.05.010
  67. Clemmensen TS, Logstrup BB, Eiskjaer H, Poulsen SH. Evaluation of longitudinal myocardial deformation by 2-dimensional speckle-tracking echocardiography in heart transplant recipients: relation to cardiac allograft vasculopathy. J Heart Lung Transplant 2015;34:195-203. https://doi.org/10.1016/j.healun.2014.07.008
  68. Buddhe S, Richimond ME, Gilbreath J, Lai WW. Longitudianl strain by speckle tracking echocardiography in pediatric heart transplant recipients. Congenit Heart Dis 2015;10:362-70. https://doi.org/10.1111/chd.12263
  69. Jeewa A, Chin C, Pahl E, Atz AM, Carboni MP, Pruitt E, et al. Outcome after percutaneous coronary artery revascularization procedures for cardiac allograft vasculoplathy in pediatric heart transplant recipients: a multi-institutional study. J Heart Lung Transplant 2015;34:1163-8. https://doi.org/10.1016/j.healun.2014.11.011

Cited by

  1. The Waiting List Mortality of Pediatric Heart Transplantation Candidates in Korea before the Pediatric Ventricular Assist Device Era vol.36, pp.44, 2021, https://doi.org/10.3346/jkms.2021.36.e283
  2. Where should we start to improve pediatric heart transplantation outcomes? vol.64, pp.2, 2021, https://doi.org/10.3345/cep.2020.00584